This program is intended for endocrinologists and scientists who are involved and/or related to research on new insulin development and the care of patients with diabetes.

Upon completing this activity, learners should be able to: 

• Identify challenges with daily basal insulin that may be overcome by weekly insulin formulations in development
• Compare the mechanism of action, efficacy, and safety of weekly insulin formulations in development with available daily basal insulins
• Evaluate strategies to address patient and provider barriers to implementing weekly insulins into clinical practice

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Endocrine Society and Clinical Care Options (CCO). The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians. 

AMA PRA Category 1 Credit

The Endocrine Society designates each activity in this course for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.50 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.

AAPA Credit

Clinical Care Options, LLC. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until July 31, 2024. PAs should only claim credit commensurate with the extent of their participation.

For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

Rodolfo Galindo, MD – Program Chair
University of Miami
Miami, FL

Juan Pablo Frias, MD
Velocity Clinical Research
Los Angeles, CA 

Carol Wysham, MD       

Multicare Rockwood Clinic

Spokane, WA

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

• Rodolfo Galindo, MD: Novo Nordisk – Research Grant, Consulting and Advisory; Eli Lilly – Research Grant, Consulting and Advisory; Dexcom – Research Grant; Sanofi – Consulting and Advisory; Pfizer - Consulting and Advisory; Boehringer - Consulting and Advisory; Bayer - Consulting and Advisory; Weight Watchers - Consulting and Advisory; National Institute of Diabetes and Digestive and Kidney Diseases – Grant Award; National Institute of Health – Grant Award.
  
  
• Juan Pablo Frias, MD: Akero – Research Support, Advisory Boards and Consulting; Boehringer Ingelheim– Research Support, Advisory Boards and Consulting; BMS – Research Support; 89bio – Research Support, Advisory Boards and Consulting; Eli Lilly – Research Support, Advisory Boards and Consulting, Speaker; Intercept – Research Support, Advisory Boards and Consulting; IONIS – Research Support; Janssen – Research Support; Madrigal – Research Support; Merck – Research Support, Advisory Boards and Consulting;  NorthSea Therapeutics – Research Support; Novartis – Research Support; Novo Nordisk – Research Support, Advisory Boards and Consulting; Oramed – Research Support; Pfizer – Research Support, Advisory Boards and Consulting; Poxel – Research Support;  Sanofi – Research Support, Advisory Boards and Consulting, Speaker; Altimmune - Advisory Boards and Consulting; Axcella Health - Advisory Boards and Consulting; Becton Dickenson -  Advisory Boards and Consulting; Carmot Therapeutics -  Advisory Boards and Consulting; Echosens -  Advisory Boards and Consulting; Gilead -  Advisory Boards and Consulting; Metacrine -  Advisory Boards and Consulting
  
  
• Carol Wysham, MD: Corcept – Investigator; Eli Lilly - Investigator; Novo Nordisk - Investigator; Regeneron - Investigator; Vanda - Investigator.

The following member who reviewed content for this activity reported no relevant financial relationships:

Milay Luis Lam, MD

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose,
except Amy Butts, PA-C as noted below:

Amy Butts, PA-C: consultant/advisor/speaker: Abbott, Bayer, Novo Nordisk, Sanofi.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.

This educational activity is supported by educational grant from Lilly USA.